Nanobots in Targeted Drug Delivery: Revolutionizing Breast Cancer Therapy with Precision

Abstract

Breast cancer continues to be a leading cause of mortality among women worldwide. Conventional chemotherapy often causes systemic toxicity and limited efficacy. Advances in nanotechnology have enabled the development of nanobots, microscopic devices capable of targeted navigation and drug delivery at tumor sites. These nanocarriers improve drug accumulation, reduce side effects, and can monitor therapeutic response. This article explores the transformative role of nanobots in precision oncology, focusing on their composition, manufacturing, evaluation, applications, commercialized examples, and recent developments in breast cancer treatment.

Keywords

Introduction

Figure 1: Nanobot Composition for targeted breast cancer therapy

Figure 2: Flowchart of nanobot drug delivery pathway from injection to clearance.

Figure 3.: Comparative outcomes of conventional chemotherapy vs. nanobot-based therapy. [13][14]

Fig 4: chemotherapy vs nanobot therapy [15]

These drugs demonstrate the clinical translation of nanocarrier-based delivery, reducing systemic toxicity and enhancing therapeutic efficacy.[16]

RECENT ADVANCES

• Protein-Bound Magnetic Nanobots: Guided by magnetic fields to improve tumor targeting. [1]
• pH-Responsive Nanobots: Release drugs selectively in acidic tumor environments.[12]
• HER2-Targeted Nanobots: Functionalized with antibodies for precision therapy.
• Integration with AI: Predictive algorithms optimize targeting and dosing, paving the way for personalized nanomedicine. [15]

CONCLUSION

Nanobots and nanocarrier-based systems represent a transformative approach in breast cancer therapy. By enabling precision-targeted delivery, reducing systemic toxicity, and offering potential theragnostic capabilities, they are poised to revolutionize oncology. Marketed examples like Doxil® and Abraxane® demonstrate real-world applicability, while ongoing research on magnetic, pH-responsive, and antibody-functionalized nanobots highlights the future of personalized, patient-centered cancer treatment. Continued advances in design, evaluation, and regulatory approval will be crucial for clinical translation.

REFERENCES

1. Naikwadi, N.; Paul, M.; Wavhale, R. Self-propelling, protein-bound magnetic nanobots for efficient in vitro drug delivery in triple-negative breast cancer cells. Sci. Rep. 2024, 14 (1), 83393-5i.
2. Cai Y.; Yang Q.; Wang J.; et al. Stimuli-Responsive nanobots for precision oncology. Nat. Nanotechnol. 2019, 14 (12), 1084–1094.
3. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160 (2), 117–134.
4. Gradishar W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 2006, 7 (8), 1041–1053.
5. Alexiou C.; et al. Targeted tumor therapy with “magnetic drug targeting”: therapeutic efficacy of ferrofluid bound mitoxantrone. Neoplasia 2000, 2 (3), 280–286.
6. Gao W.; et al. pH-responsive nanoparticles for drug delivery. J. Nanobiotechnol. 2022, 20 (1), 284.
7. Park J. W.; et al. Anti-HER2 immunoliposomes for targeted therapy of HER2-overexpressing breast cancer. ACS Chem. Biol. 2008, 3 (6), 373–382.
8. Gharatape, A.; et al. Recent advances in polymeric and lipid stimuli-responsive nanocarriers for cell-based cancer immunotherapy. Nanomedicine (Lond.) 2024, 19 (30), 2655–2678.
9. Kong, X.; Gao, P.; Hwang, K. C. Advances of medical nanorobots for future cancer treatments. J. Hematol. Oncol. 2023, 16 (1), 1–13.
10. Patra, J. K.; Das, G.; Fraceto, L. F.; Campos, E. V. R.; Rodriguez-Torres, M. del P.; Acosta-Torres, L. S.; et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 2018, 16 (1), 71.
11. Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018, 10 (2), 57.
12. Yao, Y.; Saw, P. E.; Nie, Y.; Wong, P.; Jiang, L.; Ye, X.; et al. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy. J. Mater. Chem. B 2019, 7 (4), 576–585.
13. Hruba?, M.; Ro¨sslein, M.; D’Arcy, P.; Baldi, G.; Suter, M. J. F. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J. Control. Release 2018, 282, 34–42.
14. Ibrahim, N. N.; Ali, F. M.; Ahmed, S. A. Nanorobotics: Revolutionizing Cancer Treatment And Early Diagnosis With Precision Technology. Int. J. Pharm. Sci. 2025, 15 (3), 1243–1252.
15. Kong, X.; Gao, P.; Hwang, K. C. Advances of medical nanorobots for future cancer treatments. J. Hematol. Oncol. 2023, 16 (1), 1–13.
16. Panigrahi, L.; Samal, P.; Sahoo, S. R.; Sahoo, B. Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer. Nanoscale Adv. 2024, 6 (5), 1234–1256.